Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02018250 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety of a New Oxime, MMB4 DIMETHANESULFONATE (DMS)
A Phase 1 study, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT02018250 is a Phase 1 study that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 32 participants.
The verdict
NCT02018250, a Phase 1 study, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This clinical study will evaluate escalating dosages of MMB4 DMS to determine its safety when delivered intramuscularly (i.m.) to the anterior thigh.
Interventions
- DRUG Placebo
- DRUG MMB4 DMS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2012-03-17 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02018250
The ClinicalTrials.gov registry entry for NCT02018250 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02018250 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02018250 about?
NCT02018250 is a clinical study titled "Study to Evaluate the Safety of a New Oxime, MMB4 DIMETHANESULFONATE (DMS)". This clinical study will evaluate escalating dosages of MMB4 DMS to determine its safety when delivered intramuscularly (i.m.) to the anterior thigh.
What is the current status of trial NCT02018250?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2012-03-17. Estimated completion is 2012-12.
What interventions are being tested in trial NCT02018250?
The interventions under investigation include: Placebo (DRUG), MMB4 DMS (DRUG).
Who is sponsoring clinical trial NCT02018250?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.